221 related articles for article (PubMed ID: 7621303)
1. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Tsalamandris C; Panagiotopoulos S; Sinha A; Cooper ME; Jerums G
J Cardiovasc Risk; 1994 Oct; 1(3):231-9. PubMed ID: 7621303
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.
Davignon J; Roederer G; Montigny M; Hayden MR; Tan MH; Connelly PW; Hegele R; McPherson R; Lupien PJ; Gagné C
Am J Cardiol; 1994 Feb; 73(5):339-45. PubMed ID: 8109547
[TBL] [Abstract][Full Text] [Related]
4. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
Gardner SF; Marx MA; White LM; Granberry MC; Skelton DR; Fonseca VA
Ann Pharmacother; 1997 Jun; 31(6):677-82. PubMed ID: 9184704
[TBL] [Abstract][Full Text] [Related]
5. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years.
Simons LA; Nestel PJ; Clifton P; Janus ED; Simons J; Parfitt A
Med J Aust; 1992 Nov; 157(9):584-9. PubMed ID: 1406416
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Rustemeijer C; Schouten JA; Voerman HJ; Hensgens HE; Donker AJ; Heine RJ
Diabetes Metab Res Rev; 2000; 16(2):82-7. PubMed ID: 10751747
[TBL] [Abstract][Full Text] [Related]
7. The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia.
Kinoshita M; Mikuni Y; Kudo M; Mori M; Horie E; Teramoto T; Matsushima T
J Int Med Res; 2002; 30(3):271-81. PubMed ID: 12166344
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
9. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia.
Wiklund O; Angelin B; Bergman M; Berglund L; Bondjers G; Carlsson A; Lindén T; Miettinen T; Odman B; Olofsson SO
Am J Med; 1993 Jan; 94(1):13-20. PubMed ID: 8420296
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
Farnier M; Ducobu J; Bryniarski L
Am J Cardiol; 2010 Sep; 106(6):787-92. PubMed ID: 20816118
[TBL] [Abstract][Full Text] [Related]
11. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
Mostaza JM; Schulz I; Vega GL; Grundy SM
Am J Cardiol; 1997 May; 79(9):1298-301. PubMed ID: 9164913
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus.
Krempf M; Berthezène F; Wemeau JL; Moinade S; Desriac I; Amelineau E; Passa P
Diabetes Metab; 1997 Apr; 23(2):131-6. PubMed ID: 9137901
[TBL] [Abstract][Full Text] [Related]
14. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
15. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
16. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
Rizos E; Bairaktari E; Kostoula A; Hasiotis G; Achimastos A; Ganotakis E; Elisaf M; Mikhailidis DP
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
[TBL] [Abstract][Full Text] [Related]
17. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation.
Dagli N; Yavuzkir M; Karaca I
Inflammation; 2007 Dec; 30(6):230-5. PubMed ID: 17687635
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Farnier M; Retterstøl K; Steinmetz A; Császár A
Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
